var eventsData = [{"Ticker":"IVZ","EffectiveDate":"2017-01-26","Type":"EarningsRevenueBeat","Title":"Before market open, IVZ reports 2016 Q4's earning $0.59 per share and revenue $863.8MM. This beats analyst's estimated EPS $0.58, beats estimated revenue $862.89MM.","DailyReturn":-0.03506,"FiveDayReturnAfter":-0.04945,"FiveDayReturnBefore":0.017522},{"Ticker":"IVZ","EffectiveDate":"2016-12-13","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods downgrades IVZ to Market Perform from Outperform.","DailyReturn":-0.017642,"FiveDayReturnAfter":-0.028568,"FiveDayReturnBefore":0.018429},{"Ticker":"IVZ","EffectiveDate":"2016-11-10","Type":"Dividend","Title":"The Firm pays dividend $0.28","DailyReturn":0.039919,"FiveDayReturnAfter":0.063992,"FiveDayReturnBefore":0.083844},{"Ticker":"IVZ","EffectiveDate":"2016-10-27","Type":"RevenueBeat","Title":"Before market open, IVZ reports 2016 Q3's earning $0.6 per share and revenue $854.7MM. This meets analyst's estimated EPS $0.6, misses estimated revenue $863.53MM.","DailyReturn":-0.020539,"FiveDayReturnAfter":-0.070799,"FiveDayReturnBefore":-0.001683},{"Ticker":"IVZ","EffectiveDate":"2016-10-14","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform.","DailyReturn":-0.013197,"FiveDayReturnAfter":-0.016299,"FiveDayReturnBefore":-0.048931},{"Ticker":"IVZ","EffectiveDate":"2016-10-14","Type":"RatingNeutral","Title":"Deutsche Bank downgrades IVZ to Hold from Buy.","DailyReturn":-0.013197,"FiveDayReturnAfter":-0.016299,"FiveDayReturnBefore":-0.048931},{"Ticker":"IVZ","EffectiveDate":"2016-10-13","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight.","DailyReturn":-0.015909,"FiveDayReturnAfter":-0.034686,"FiveDayReturnBefore":-0.037283},{"Ticker":"IVZ","EffectiveDate":"2016-10-11","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy.","DailyReturn":-0.02272,"FiveDayReturnAfter":-0.055259,"FiveDayReturnBefore":-0.006697},{"Ticker":"IVZ","EffectiveDate":"2016-10-05","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $36; previously $35.","DailyReturn":0.018477,"FiveDayReturnAfter":-0.027452,"FiveDayReturnBefore":0.021902},{"Ticker":"IVZ","EffectiveDate":"2016-10-04","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Neutral. Target Price is $33; previously $31.","DailyReturn":-0.002225,"FiveDayReturnAfter":-0.006697,"FiveDayReturnBefore":0.03823},{"Ticker":"IVZ","EffectiveDate":"2016-09-09","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $35; previously $34.","DailyReturn":-0.022547,"FiveDayReturnAfter":-0.025407,"FiveDayReturnBefore":0.009574},{"Ticker":"IVZ","EffectiveDate":"2016-08-16","Type":"Dividend","Title":"The Firm pays dividend $0.28","DailyReturn":0.002698,"FiveDayReturnAfter":0.021025,"FiveDayReturnBefore":0.007714},{"Ticker":"IVZ","EffectiveDate":"2016-08-09","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $36; previously $35.","DailyReturn":-0.007407,"FiveDayReturnAfter":0.007714,"FiveDayReturnBefore":0.022472},{"Ticker":"IVZ","EffectiveDate":"2016-08-05","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $34; previously $33.","DailyReturn":0.021784,"FiveDayReturnAfter":0.026613,"FiveDayReturnBefore":-0.000001},{"Ticker":"IVZ","EffectiveDate":"2016-07-29","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $35; previously $34.","DailyReturn":0.00899,"FiveDayReturnAfter":-0.000001,"FiveDayReturnBefore":0.028407},{"Ticker":"IVZ","EffectiveDate":"2016-07-29","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Neutral. Target Price is $31; previously $27.","DailyReturn":0.00899,"FiveDayReturnAfter":-0.000001,"FiveDayReturnBefore":0.028407},{"Ticker":"IVZ","EffectiveDate":"2016-07-29","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $34; previously $33.","DailyReturn":0.00899,"FiveDayReturnAfter":-0.000001,"FiveDayReturnBefore":0.028407},{"Ticker":"IVZ","EffectiveDate":"2016-07-29","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $37; previously $36.","DailyReturn":0.00899,"FiveDayReturnAfter":-0.000001,"FiveDayReturnBefore":0.028407},{"Ticker":"IVZ","EffectiveDate":"2016-07-28","Type":"EarningsRevenueBeat","Title":"Before market open, IVZ reports 2016 Q2's earning $0.56 per share and revenue $856.6MM. This beats analyst's estimated EPS $0.55, beats estimated revenue $848.82MM.","DailyReturn":0.010835,"FiveDayReturnAfter":0.014228,"FiveDayReturnBefore":0.021194},{"Ticker":"IVZ","EffectiveDate":"2016-07-18","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $33; previously $32.","DailyReturn":0.009482,"FiveDayReturnAfter":0.036875,"FiveDayReturnBefore":0.067509},{"Ticker":"IVZ","EffectiveDate":"2016-07-11","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $30; previously $35.","DailyReturn":0.007413,"FiveDayReturnAfter":0.067509,"FiveDayReturnBefore":0.003519},{"Ticker":"IVZ","EffectiveDate":"2016-07-07","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $35; previously $37.","DailyReturn":0.006803,"FiveDayReturnAfter":0.065439,"FiveDayReturnBefore":0.040839},{"Ticker":"IVZ","EffectiveDate":"2016-06-27","Type":"RatingNeutral","Title":"Citigroup downgrades IVZ to Neutral from Buy. Target Price is $27; previously $38.","DailyReturn":-0.094251,"FiveDayReturnAfter":-0.00943,"FiveDayReturnBefore":-0.081094},{"Ticker":"IVZ","EffectiveDate":"2016-06-16","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $34; previously $35.","DailyReturn":0.004015,"FiveDayReturnAfter":0.048791,"FiveDayReturnBefore":-0.076894},{"Ticker":"IVZ","EffectiveDate":"2016-06-02","Type":"RatingNeutral","Title":"UBS downgrades IVZ to Neutral from Buy.","DailyReturn":-0.015331,"FiveDayReturnAfter":-0.056501,"FiveDayReturnBefore":0.018699},{"Ticker":"IVZ","EffectiveDate":"2016-05-11","Type":"Dividend","Title":"The Firm pays dividend $0.28","DailyReturn":-0.022215,"FiveDayReturnAfter":-0.044742,"FiveDayReturnBefore":-0.004658},{"Ticker":"IVZ","EffectiveDate":"2016-04-28","Type":"EarningsRevenueMiss","Title":"Before market open, IVZ reports 2016 Q1's earning $0.49 per share and revenue $818.1MM. This misses analyst's estimated EPS $0.54, misses estimated revenue $855.66MM.","DailyReturn":-0.037886,"FiveDayReturnAfter":-0.096471,"FiveDayReturnBefore":0.010751},{"Ticker":"IVZ","EffectiveDate":"2016-04-07","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $39; previously $36.","DailyReturn":-0.037711,"FiveDayReturnAfter":0.014845,"FiveDayReturnBefore":-0.016125},{"Ticker":"IVZ","EffectiveDate":"2016-04-05","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $36; previously $34.","DailyReturn":-0.012866,"FiveDayReturnAfter":-0.048435,"FiveDayReturnBefore":0.019487},{"Ticker":"IVZ","EffectiveDate":"2016-04-01","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $35; previously $32.","DailyReturn":0.019824,"FiveDayReturnAfter":-0.038766,"FiveDayReturnBefore":0.012097},{"Ticker":"IVZ","EffectiveDate":"2016-03-17","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $34; previously $33.","DailyReturn":0.02622,"FiveDayReturnAfter":0.008922,"FiveDayReturnBefore":0.066554},{"Ticker":"IVZ","EffectiveDate":"2016-02-16","Type":"Dividend","Title":"The Firm pays dividend $0.27","DailyReturn":0.017918,"FiveDayReturnAfter":0.035577,"FiveDayReturnBefore":-0.021652},{"Ticker":"IVZ","EffectiveDate":"2016-02-09","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $36; previously $39.","DailyReturn":-0.005043,"FiveDayReturnAfter":0.045304,"FiveDayReturnBefore":-0.121827},{"Ticker":"IVZ","EffectiveDate":"2016-02-09","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $32; previously $35.","DailyReturn":-0.005043,"FiveDayReturnAfter":0.045304,"FiveDayReturnBefore":-0.121827},{"Ticker":"IVZ","EffectiveDate":"2016-02-09","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $32; previously $34.","DailyReturn":-0.005043,"FiveDayReturnAfter":0.045304,"FiveDayReturnBefore":-0.121827},{"Ticker":"IVZ","EffectiveDate":"2016-01-19","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $33; previously $36.","DailyReturn":0.002086,"FiveDayReturnAfter":-0.003832,"FiveDayReturnBefore":-0.046535},{"Ticker":"IVZ","EffectiveDate":"2016-01-11","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $40; previously $41.","DailyReturn":-0.006638,"FiveDayReturnAfter":-0.046535,"FiveDayReturnBefore":-0.105429},{"Ticker":"IVZ","EffectiveDate":"2015-12-16","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $39; previously $43.","DailyReturn":0.017869,"FiveDayReturnAfter":0.012368,"FiveDayReturnBefore":-0.047057},{"Ticker":"IVZ","EffectiveDate":"2015-11-13","Type":"Dividend","Title":"The Firm pays dividend $0.27","DailyReturn":-0.015213,"FiveDayReturnAfter":0.029971,"FiveDayReturnBefore":-0.042498},{"Ticker":"IVZ","EffectiveDate":"2015-10-08","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $39; previously $41.","DailyReturn":0.004242,"FiveDayReturnAfter":-0.058657,"FiveDayReturnBefore":0.05513},{"Ticker":"IVZ","EffectiveDate":"2015-10-07","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $39; previously $46.","DailyReturn":0.015385,"FiveDayReturnAfter":-0.032523,"FiveDayReturnBefore":0.053077},{"Ticker":"IVZ","EffectiveDate":"2015-09-10","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $48; previously $51.","DailyReturn":0.006456,"FiveDayReturnAfter":0.035632,"FiveDayReturnBefore":-0.011614},{"Ticker":"IVZ","EffectiveDate":"2015-09-08","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $40; previously $45.","DailyReturn":0.03036,"FiveDayReturnAfter":0.021979,"FiveDayReturnBefore":-0.07997},{"Ticker":"IVZ","EffectiveDate":"2015-09-03","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $43; previously $49.","DailyReturn":-0.00182,"FiveDayReturnAfter":-0.006697,"FiveDayReturnBefore":-0.006953},{"Ticker":"IVZ","EffectiveDate":"2015-09-03","Type":"RatingNeutral","Title":"Susquehanna maintains IVZ to Positive. Target Price is $39; previously $45.","DailyReturn":-0.00182,"FiveDayReturnAfter":-0.006697,"FiveDayReturnBefore":-0.006953},{"Ticker":"IVZ","EffectiveDate":"2015-08-18","Type":"Dividend","Title":"The Firm pays dividend $0.27","DailyReturn":-0.004547,"FiveDayReturnAfter":-0.128539,"FiveDayReturnBefore":-0.031623},{"Ticker":"IVZ","EffectiveDate":"2015-07-31","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $45; previously $44.","DailyReturn":-0.010003,"FiveDayReturnAfter":-0.010055,"FiveDayReturnBefore":0.025719},{"Ticker":"IVZ","EffectiveDate":"2015-07-20","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $44; previously $43.","DailyReturn":-0.003897,"FiveDayReturnAfter":-0.02659,"FiveDayReturnBefore":0.041374},{"Ticker":"IVZ","EffectiveDate":"2015-07-14","Type":"RatingNeutral","Title":"Credit Suisse maintains IVZ to Neutral. Target Price is $46; previously $48.","DailyReturn":0.013604,"FiveDayReturnAfter":0.022419,"FiveDayReturnBefore":0.006154},{"Ticker":"IVZ","EffectiveDate":"2015-07-10","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $44; previously $47.","DailyReturn":0.013169,"FiveDayReturnAfter":0.057311,"FiveDayReturnBefore":-0.036632},{"Ticker":"IVZ","EffectiveDate":"2015-07-09","Type":"RatingNeutral","Title":"Susquehanna maintains IVZ to Positive. Target Price is $44; previously $48.","DailyReturn":0.00635,"FiveDayReturnAfter":0.046658,"FiveDayReturnBefore":-0.034462},{"Ticker":"IVZ","EffectiveDate":"2015-06-08","Type":"RatingNeutral","Title":"Goldman Sachs initiates coverage on IVZ to Neutral. Target Price is $44.","DailyReturn":0.003316,"FiveDayReturnAfter":0.006864,"FiveDayReturnBefore":-0.015945},{"Ticker":"IVZ","EffectiveDate":"2015-06-03","Type":"RatingNeutral","Title":"PiperJaffray initiates coverage on IVZ to Overweight. Target Price is $50.","DailyReturn":-0.000753,"FiveDayReturnAfter":-0.021812,"FiveDayReturnBefore":-0.003259},{"Ticker":"IVZ","EffectiveDate":"2015-05-13","Type":"Dividend","Title":"The Firm pays dividend $0.27","DailyReturn":-0.006165,"FiveDayReturnAfter":-0.004448,"FiveDayReturnBefore":-0.00708},{"Ticker":"IVZ","EffectiveDate":"2015-05-01","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $52; previously $51.","DailyReturn":0.004587,"FiveDayReturnAfter":-0.009946,"FiveDayReturnBefore":0.014837},{"Ticker":"IVZ","EffectiveDate":"2015-04-13","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $45; previously $44.","DailyReturn":0.00675,"FiveDayReturnAfter":-0.003003,"FiveDayReturnBefore":0.003255},{"Ticker":"IVZ","EffectiveDate":"2015-04-10","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $47; previously $45.","DailyReturn":-0.004975,"FiveDayReturnAfter":0.007437,"FiveDayReturnBefore":0.010501},{"Ticker":"IVZ","EffectiveDate":"2015-04-08","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $51; previously $52.","DailyReturn":0.007042,"FiveDayReturnAfter":0.01349,"FiveDayReturnBefore":-0.006019},{"Ticker":"IVZ","EffectiveDate":"2015-04-02","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $44; previously $45.","DailyReturn":0.002262,"FiveDayReturnAfter":0.010501,"FiveDayReturnBefore":-0.007513},{"Ticker":"IVZ","EffectiveDate":"2015-03-06","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $45; previously $44.","DailyReturn":-0.011574,"FiveDayReturnAfter":-0.000494,"FiveDayReturnBefore":0.006918},{"Ticker":"IVZ","EffectiveDate":"2015-03-05","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Market Perform. Target Price is $52; previously $47.","DailyReturn":0.006693,"FiveDayReturnAfter":-0.01373,"FiveDayReturnBefore":0.003725},{"Ticker":"IVZ","EffectiveDate":"2015-03-05","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $46; previously $44.","DailyReturn":0.006693,"FiveDayReturnAfter":-0.01373,"FiveDayReturnBefore":0.003725},{"Ticker":"IVZ","EffectiveDate":"2015-02-17","Type":"Dividend","Title":"The Firm pays dividend $0.25","DailyReturn":0.006111,"FiveDayReturnAfter":0.011897,"FiveDayReturnBefore":0.017099},{"Ticker":"IVZ","EffectiveDate":"2015-01-30","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $48; previously $50.","DailyReturn":-0.027535,"FiveDayReturnAfter":0.030251,"FiveDayReturnBefore":0.011985},{"Ticker":"IVZ","EffectiveDate":"2015-01-26","Type":"RatingUpgrade","Title":"Susquehanna upgrades IVZ to Positive from Neutral.","DailyReturn":0.009992,"FiveDayReturnAfter":-0.008135,"FiveDayReturnBefore":0.030156},{"Ticker":"IVZ","EffectiveDate":"2015-01-08","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $47; previously $48.","DailyReturn":0.017507,"FiveDayReturnAfter":-0.030978,"FiveDayReturnBefore":-0.058218},{"Ticker":"IVZ","EffectiveDate":"2015-01-07","Type":"RatingUpgrade","Title":"Sterne Agee upgrades IVZ to Buy from Neutral. Target Price is $47; previously $45.","DailyReturn":0.013169,"FiveDayReturnAfter":0.003221,"FiveDayReturnBefore":-0.081013},{"Ticker":"IVZ","EffectiveDate":"2015-01-06","Type":"RatingNeutral","Title":"Credit Suisse downgrades IVZ to Neutral from Outperform. Target Price is $45.","DailyReturn":-0.020789,"FiveDayReturnAfter":-0.015111,"FiveDayReturnBefore":-0.059261},{"Ticker":"IVZ","EffectiveDate":"2014-12-10","Type":"RatingNeutral","Title":"Credit Suisse maintains IVZ to Outperform. Target Price is $45; previously $44.","DailyReturn":-0.0202,"FiveDayReturnAfter":-0.073715,"FiveDayReturnBefore":0.014464},{"Ticker":"IVZ","EffectiveDate":"2014-12-09","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Market Perform. Target Price is $48; previously $45.","DailyReturn":0.000731,"FiveDayReturnAfter":-0.0623,"FiveDayReturnBefore":0.018931},{"Ticker":"IVZ","EffectiveDate":"2014-12-04","Type":"RatingNeutral","Title":"Barclays initiates coverage on IVZ to Overweight. Target Price is $45.","DailyReturn":0.000495,"FiveDayReturnAfter":-0.00446,"FiveDayReturnBefore":0.000246},{"Ticker":"IVZ","EffectiveDate":"2014-11-14","Type":"Dividend","Title":"The Firm pays dividend $0.25","DailyReturn":-0.007171,"FiveDayReturnAfter":-0.013443,"FiveDayReturnBefore":-0.00637},{"Ticker":"IVZ","EffectiveDate":"2014-10-14","Type":"RatingNeutral","Title":"Bank of America maintains IVZ to Buy. Target Price is $43; previously $45.","DailyReturn":-0.009151,"FiveDayReturnAfter":0.017594,"FiveDayReturnBefore":-0.092886},{"Ticker":"IVZ","EffectiveDate":"2014-10-14","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $44; previously $46.","DailyReturn":-0.009151,"FiveDayReturnAfter":0.017594,"FiveDayReturnBefore":-0.092886},{"Ticker":"IVZ","EffectiveDate":"2014-10-08","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $45; previously $46.","DailyReturn":0.008817,"FiveDayReturnAfter":-0.076224,"FiveDayReturnBefore":-0.023578},{"Ticker":"IVZ","EffectiveDate":"2014-09-11","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $45; previously $43.","DailyReturn":0.006424,"FiveDayReturnAfter":0.009346,"FiveDayReturnBefore":-0.006159},{"Ticker":"IVZ","EffectiveDate":"2014-08-19","Type":"Dividend","Title":"The Firm pays dividend $0.25","DailyReturn":0.008155,"FiveDayReturnAfter":0.034317,"FiveDayReturnBefore":0.028773},{"Ticker":"IVZ","EffectiveDate":"2014-08-08","Type":"RatingNeutral","Title":"Argus Research maintains IVZ to Buy. Target Price is $45; previously $42.","DailyReturn":0.001058,"FiveDayReturnAfter":0.037632,"FiveDayReturnBefore":0.004771},{"Ticker":"IVZ","EffectiveDate":"2014-08-01","Type":"RatingUpgrade","Title":"Deutsche Bank upgrades IVZ to Buy from Hold. Target Price is $43; previously $39.","DailyReturn":0.005049,"FiveDayReturnAfter":0.004771,"FiveDayReturnBefore":-0.024154},{"Ticker":"IVZ","EffectiveDate":"2014-08-01","Type":"RatingNeutral","Title":"UBS maintains IVZ to Neutral. Target Price is $40; previously $37.","DailyReturn":0.005049,"FiveDayReturnAfter":0.004771,"FiveDayReturnBefore":-0.024154},{"Ticker":"IVZ","EffectiveDate":"2014-08-01","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $46; previously $45.","DailyReturn":0.005049,"FiveDayReturnAfter":0.004771,"FiveDayReturnBefore":-0.024154},{"Ticker":"IVZ","EffectiveDate":"2014-07-08","Type":"RatingNeutral","Title":"Credit Suisse maintains IVZ to Outperform. Target Price is $44; previously $42.","DailyReturn":-0.015762,"FiveDayReturnAfter":-0.015627,"FiveDayReturnBefore":0.025118},{"Ticker":"IVZ","EffectiveDate":"2014-07-01","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $43; previously $42.","DailyReturn":0.015894,"FiveDayReturnAfter":0.008965,"FiveDayReturnBefore":0.005311},{"Ticker":"IVZ","EffectiveDate":"2014-07-01","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $44; previously $40.","DailyReturn":0.015894,"FiveDayReturnAfter":0.008965,"FiveDayReturnBefore":0.005311},{"Ticker":"IVZ","EffectiveDate":"2014-05-20","Type":"RatingUpgrade","Title":"JP Morgan upgrades IVZ to Overweight from Neutral. Target Price is $42; previously $41.","DailyReturn":-0.005125,"FiveDayReturnAfter":0.026135,"FiveDayReturnBefore":-0.022498},{"Ticker":"IVZ","EffectiveDate":"2014-05-16","Type":"RatingNeutral","Title":"Deutsche Bank initiates coverage on IVZ to Hold. Target Price is $39.","DailyReturn":0.002022,"FiveDayReturnAfter":0.022845,"FiveDayReturnBefore":-0.018704},{"Ticker":"IVZ","EffectiveDate":"2014-05-14","Type":"Dividend","Title":"The Firm pays dividend $0.25","DailyReturn":-0.005868,"FiveDayReturnAfter":-0.024036,"FiveDayReturnBefore":0.021881},{"Ticker":"IVZ","EffectiveDate":"2014-05-02","Type":"RatingNeutral","Title":"UBS maintains IVZ to Neutral. Target Price is $37; previously $36.","DailyReturn":-0.001666,"FiveDayReturnAfter":-0.013979,"FiveDayReturnBefore":0.017928},{"Ticker":"IVZ","EffectiveDate":"2014-05-02","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Neutral. Target Price is $41; previously $39.","DailyReturn":-0.001666,"FiveDayReturnAfter":-0.013979,"FiveDayReturnBefore":0.017928},{"Ticker":"IVZ","EffectiveDate":"2014-04-15","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Neutral. Target Price is $39; previously $38.","DailyReturn":0.006394,"FiveDayReturnAfter":0.037084,"FiveDayReturnBefore":-0.006373},{"Ticker":"IVZ","EffectiveDate":"2014-04-10","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $47; previously $48.","DailyReturn":-0.023347,"FiveDayReturnAfter":-0.010462,"FiveDayReturnBefore":-0.058188},{"Ticker":"IVZ","EffectiveDate":"2014-04-09","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $47; previously $48.","DailyReturn":0.011956,"FiveDayReturnAfter":-0.014334,"FiveDayReturnBefore":-0.064217},{"Ticker":"IVZ","EffectiveDate":"2014-02-18","Type":"Dividend","Title":"The Firm pays dividend $0.225","DailyReturn":0.000146,"FiveDayReturnAfter":-0.008975,"FiveDayReturnBefore":0.044028},{"Ticker":"IVZ","EffectiveDate":"2014-01-31","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $48; previously $44.","DailyReturn":-0.007463,"FiveDayReturnAfter":-0.022642,"FiveDayReturnBefore":-0.043517},{"Ticker":"IVZ","EffectiveDate":"2013-11-15","Type":"Dividend","Title":"The Firm pays dividend $0.225","DailyReturn":-0.000148,"FiveDayReturnAfter":-0.001921,"FiveDayReturnBefore":0.051186},{"Ticker":"IVZ","EffectiveDate":"2013-11-14","Type":"RatingUpgrade","Title":"Goldman Sachs upgrades IVZ to Buy from Neutral. Target Price is $38; previously $35.","DailyReturn":0.023738,"FiveDayReturnAfter":0.012619,"FiveDayReturnBefore":0.006633},{"Ticker":"IVZ","EffectiveDate":"2013-11-11","Type":"RatingUpgrade","Title":"Wells Fargo upgrades IVZ to Outperform from Market Perform.","DailyReturn":0.007503,"FiveDayReturnAfter":0.022112,"FiveDayReturnBefore":-0.015485},{"Ticker":"IVZ","EffectiveDate":"2013-10-31","Type":"EarningsBeatRevenueMiss","Title":"Before market open, IVZ reports 2013 Q3's earning $0.55 per share and revenue $816.4MM. This beats analyst's estimated EPS $0.52, misses estimated revenue $1170MM.","DailyReturn":0.025524,"FiveDayReturnAfter":0.004548,"FiveDayReturnBefore":0.013767},{"Ticker":"IVZ","EffectiveDate":"2013-10-16","Type":"RatingNeutral","Title":"JP Morgan downgrades IVZ to Neutral from Overweight. Target Price is $36; previously $41.","DailyReturn":-0.010796,"FiveDayReturnAfter":0.002465,"FiveDayReturnBefore":0.028788},{"Ticker":"IVZ","EffectiveDate":"2013-10-16","Type":"RatingNeutral","Title":"Sterne Agee initiates coverage on IVZ to Neutral. Target Price is $33.","DailyReturn":-0.010796,"FiveDayReturnAfter":0.002465,"FiveDayReturnBefore":0.028788},{"Ticker":"IVZ","EffectiveDate":"2013-08-19","Type":"Dividend","Title":"The Firm pays dividend $0.225","DailyReturn":-0.019331,"FiveDayReturnAfter":-0.007731,"FiveDayReturnBefore":-0.016407},{"Ticker":"IVZ","EffectiveDate":"2013-07-25","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $36; previously $38.","DailyReturn":0.003365,"FiveDayReturnAfter":-0.015414,"FiveDayReturnBefore":0.026976},{"Ticker":"IVZ","EffectiveDate":"2013-07-10","Type":"RatingNeutral","Title":"Evercore Partners initiates coverage on IVZ to Equal-Weight. Target Price is $35.","DailyReturn":-0.022153,"FiveDayReturnAfter":-0.003438,"FiveDayReturnBefore":0.009403},{"Ticker":"IVZ","EffectiveDate":"2013-06-17","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $39; previously $37.","DailyReturn":0.024761,"FiveDayReturnAfter":-0.02141,"FiveDayReturnBefore":-0.027077},{"Ticker":"IVZ","EffectiveDate":"2013-05-15","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $38; previously $35.","DailyReturn":0.010072,"FiveDayReturnAfter":0.005386,"FiveDayReturnBefore":0.055762},{"Ticker":"IVZ","EffectiveDate":"2013-05-15","Type":"Dividend","Title":"The Firm pays dividend $0.225","DailyReturn":0.010072,"FiveDayReturnAfter":0.005386,"FiveDayReturnBefore":0.055762},{"Ticker":"IVZ","EffectiveDate":"2013-05-13","Type":"RatingNeutral","Title":"UBS downgrades IVZ to Neutral from Buy.","DailyReturn":-0.002052,"FiveDayReturnAfter":0.020521,"FiveDayReturnBefore":0.049584},{"Ticker":"IVZ","EffectiveDate":"2013-05-02","Type":"RatingUpgrade","Title":"Sterne Agee upgrades IVZ to Buy from Neutral. Target Price is $37; previously $33.","DailyReturn":0.01145,"FiveDayReturnAfter":0.048428,"FiveDayReturnBefore":0.057607},{"Ticker":"IVZ","EffectiveDate":"2013-05-01","Type":"RatingNeutral","Title":"Nomura maintains IVZ to Buy. Target Price is $35; previously $32.","DailyReturn":-0.009452,"FiveDayReturnAfter":0.027042,"FiveDayReturnBefore":0.066767},{"Ticker":"IVZ","EffectiveDate":"2013-04-30","Type":"EarningsRelease","Title":"Before market open, IVZ reports 2013 Q1's earning $0.52 per share and revenue $1142MM..","DailyReturn":0.068327,"FiveDayReturnAfter":0.092215,"FiveDayReturnBefore":0.017315},{"Ticker":"IVZ","EffectiveDate":"2013-04-23","Type":"RatingUpgrade","Title":"JP Morgan upgrades IVZ to Overweight from Neutral. Target Price is $34; previously $31.","DailyReturn":0.016781,"FiveDayReturnAfter":0.017315,"FiveDayReturnBefore":0.008599},{"Ticker":"IVZ","EffectiveDate":"2013-04-12","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $35; previously $34.","DailyReturn":-0.001657,"FiveDayReturnAfter":-0.063611,"FiveDayReturnBefore":0.050629},{"Ticker":"IVZ","EffectiveDate":"2013-04-05","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $33; previously $31.","DailyReturn":-0.011154,"FiveDayReturnAfter":0.050629,"FiveDayReturnBefore":0.001395},{"Ticker":"IVZ","EffectiveDate":"2013-04-05","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $33; previously $31.","DailyReturn":-0.011154,"FiveDayReturnAfter":0.050629,"FiveDayReturnBefore":0.001395},{"Ticker":"IVZ","EffectiveDate":"2013-03-01","Type":"RatingNeutral","Title":"Susquehanna initiates coverage on IVZ to Neutral. Target Price is $29.","DailyReturn":0.001493,"FiveDayReturnAfter":0.042031,"FiveDayReturnBefore":0.018461},{"Ticker":"IVZ","EffectiveDate":"2013-02-19","Type":"Dividend","Title":"The Firm pays dividend $0.172","DailyReturn":0.017361,"FiveDayReturnAfter":-0.047373,"FiveDayReturnBefore":0.001829},{"Ticker":"IVZ","EffectiveDate":"2013-02-05","Type":"RatingNeutral","Title":"BMO Capital downgrades IVZ to Market Perform from Outperform. Target Price is $29.","DailyReturn":0.011364,"FiveDayReturnAfter":0.005484,"FiveDayReturnBefore":-0.025695},{"Ticker":"IVZ","EffectiveDate":"2013-02-01","Type":"RatingNeutral","Title":"Stifel Nicolaus maintains IVZ to Buy. Target Price is $30; previously $29.","DailyReturn":0.019083,"FiveDayReturnAfter":0.003298,"FiveDayReturnBefore":-0.018905},{"Ticker":"IVZ","EffectiveDate":"2013-02-01","Type":"RatingNeutral","Title":"Morgan Stanley downgrades IVZ to Equal-Weight from Overweight. Target Price is $30.","DailyReturn":0.019083,"FiveDayReturnAfter":0.003298,"FiveDayReturnBefore":-0.018905},{"Ticker":"IVZ","EffectiveDate":"2013-01-31","Type":"EarningsRevenueMiss","Title":"Before market open, IVZ reports 2012 Q4's earning $0.45 per share and revenue $1090MM. This misses analyst's estimated EPS $0.47, misses estimated revenue $1110MM.","DailyReturn":-0.036422,"FiveDayReturnAfter":-0.027969,"FiveDayReturnBefore":0.0247},{"Ticker":"IVZ","EffectiveDate":"2013-01-14","Type":"RatingNeutral","Title":"JP Morgan downgrades IVZ to Neutral from Overweight. Target Price is $31; previously $32.","DailyReturn":-0.01442,"FiveDayReturnAfter":-0.002888,"FiveDayReturnBefore":0.006509},{"Ticker":"IVZ","EffectiveDate":"2012-11-15","Type":"Dividend","Title":"The Firm pays dividend $0.173","DailyReturn":0.002722,"FiveDayReturnAfter":0.049434,"FiveDayReturnBefore":-0.024567},{"Ticker":"IVZ","EffectiveDate":"2012-11-07","Type":"RatingNeutral","Title":"Bank of America assumes IVZ to Buy. Target Price is $30.","DailyReturn":-0.031212,"FiveDayReturnAfter":-0.030037,"FiveDayReturnBefore":0.017173},{"Ticker":"IVZ","EffectiveDate":"2012-11-02","Type":"RatingNeutral","Title":"Credit Suisse maintains IVZ to Outperform. Target Price is $27; previously $28.","DailyReturn":-0.013743,"FiveDayReturnAfter":-0.040838,"FiveDayReturnBefore":0.027872},{"Ticker":"IVZ","EffectiveDate":"2012-11-02","Type":"RatingNeutral","Title":"Nomura maintains IVZ to Buy. Target Price is $29; previously $28.","DailyReturn":-0.013743,"FiveDayReturnAfter":-0.040838,"FiveDayReturnBefore":0.027872},{"Ticker":"IVZ","EffectiveDate":"2012-11-01","Type":"EarningsRevenueMiss","Title":"IVZ reports 2012 Q3's earning $0.42 per share and revenue $1040MM. This misses analyst's estimated EPS $0.45, misses estimated revenue $1060MM.","DailyReturn":0.01727,"FiveDayReturnAfter":-0.017419,"FiveDayReturnBefore":-0.008597},{"Ticker":"IVZ","EffectiveDate":"2012-10-04","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $33; previously $27.5.","DailyReturn":0.012219,"FiveDayReturnAfter":-0.015893,"FiveDayReturnBefore":0.030821},{"Ticker":"IVZ","EffectiveDate":"2012-09-13","Type":"RatingNeutral","Title":"UBS maintains IVZ to Buy. Target Price is $29; previously $28.","DailyReturn":0.026821,"FiveDayReturnAfter":0.023735,"FiveDayReturnBefore":0.046291},{"Ticker":"IVZ","EffectiveDate":"2012-08-24","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $29; previously $28.","DailyReturn":0.005917,"FiveDayReturnAfter":-0.00721,"FiveDayReturnBefore":-0.009542},{"Ticker":"IVZ","EffectiveDate":"2012-08-20","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $27.5; previously $27.","DailyReturn":-0.002807,"FiveDayReturnAfter":-0.002811,"FiveDayReturnBefore":0.014244},{"Ticker":"IVZ","EffectiveDate":"2012-08-20","Type":"Dividend","Title":"The Firm pays dividend $0.173","DailyReturn":-0.002807,"FiveDayReturnAfter":-0.002811,"FiveDayReturnBefore":0.014244},{"Ticker":"IVZ","EffectiveDate":"2012-07-27","Type":"RatingNeutral","Title":"Morgan Stanley maintains IVZ to Overweight. Target Price is $29; previously $28.","DailyReturn":0.057867,"FiveDayReturnAfter":0.037545,"FiveDayReturnBefore":-0.066152},{"Ticker":"IVZ","EffectiveDate":"2012-07-27","Type":"RatingNeutral","Title":"BMO Capital maintains IVZ to Outperform. Target Price is $26; previously $27.","DailyReturn":0.057867,"FiveDayReturnAfter":0.037545,"FiveDayReturnBefore":-0.066152},{"Ticker":"IVZ","EffectiveDate":"2012-07-26","Type":"EarningsRevenueMiss","Title":"Before market open, IVZ reports 2012 Q2's earning $0.41 per share and revenue $1010MM. This misses analyst's estimated EPS $0.43, misses estimated revenue $1040MM.","DailyReturn":0.020498,"FiveDayReturnAfter":0.06655,"FiveDayReturnBefore":-0.085547},{"Ticker":"IVZ","EffectiveDate":"2012-07-16","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $27; previously $28.","DailyReturn":-0.023841,"FiveDayReturnAfter":-0.050248,"FiveDayReturnBefore":0.022776},{"Ticker":"IVZ","EffectiveDate":"2012-07-10","Type":"RatingNeutral","Title":"Morgan Stanley maintains IVZ to Overweight. Target Price is $28; previously $29.","DailyReturn":0.006856,"FiveDayReturnAfter":0.010458,"FiveDayReturnBefore":-0.032378},{"Ticker":"IVZ","EffectiveDate":"2012-07-09","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $26; previously $30.","DailyReturn":-0.011743,"FiveDayReturnAfter":0.022776,"FiveDayReturnBefore":0.015015},{"Ticker":"IVZ","EffectiveDate":"2012-06-21","Type":"RatingNeutral","Title":"Argus Research initiates coverage on IVZ to Buy.","DailyReturn":-0.030631,"FiveDayReturnAfter":-0.026474,"FiveDayReturnBefore":0.024625},{"Ticker":"IVZ","EffectiveDate":"2012-05-18","Type":"RatingNeutral","Title":"UBS maintains IVZ to Buy. Target Price is $28; previously $29.","DailyReturn":-0.022212,"FiveDayReturnAfter":-0.000464,"FiveDayReturnBefore":-0.043248},{"Ticker":"IVZ","EffectiveDate":"2012-05-16","Type":"Dividend","Title":"The Firm pays dividend $0.173","DailyReturn":-0.011516,"FiveDayReturnAfter":-0.04383,"FiveDayReturnBefore":-0.04052},{"Ticker":"IVZ","EffectiveDate":"2012-05-10","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $28.5; previously $31.","DailyReturn":-0.021093,"FiveDayReturnAfter":-0.043957,"FiveDayReturnBefore":-0.063382},{"Ticker":"IVZ","EffectiveDate":"2012-04-27","Type":"RatingNeutral","Title":"Credit Suisse maintains IVZ to Outperform. Target Price is $32; previously $31.","DailyReturn":0.001596,"FiveDayReturnAfter":-0.029152,"FiveDayReturnBefore":0.031208},{"Ticker":"IVZ","EffectiveDate":"2012-04-26","Type":"EarningsRelease","Title":"Before market open, IVZ reports 2012 Q1's earning $0.43 per share and revenue $1033MM..","DailyReturn":0.024949,"FiveDayReturnAfter":0.012196,"FiveDayReturnBefore":-0.002043},{"Ticker":"IVZ","EffectiveDate":"2012-04-10","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $30; previously $26.","DailyReturn":-0.029377,"FiveDayReturnAfter":-0.020453,"FiveDayReturnBefore":-0.057092},{"Ticker":"IVZ","EffectiveDate":"2012-04-09","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $30; previously $26.","DailyReturn":-0.031899,"FiveDayReturnAfter":-0.051657,"FiveDayReturnBefore":-0.004218},{"Ticker":"IVZ","EffectiveDate":"2012-03-08","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $30; previously $27.","DailyReturn":0.014015,"FiveDayReturnAfter":0.068114,"FiveDayReturnBefore":-0.020804},{"Ticker":"IVZ","EffectiveDate":"2012-02-21","Type":"Dividend","Title":"The Firm pays dividend $0.123","DailyReturn":0.009073,"FiveDayReturnAfter":0.007822,"FiveDayReturnBefore":0.024591},{"Ticker":"IVZ","EffectiveDate":"2012-02-21","Type":"RatingNeutral","Title":"UBS maintains IVZ to Buy. Target Price is $28; previously $25.","DailyReturn":0.009073,"FiveDayReturnAfter":0.007822,"FiveDayReturnBefore":0.024591}];